The trial is taking place at:
U

University of Massachusetts | Chan Medical School - Aaron Lazare Medical Research Building - Dermatology Department

Veeva-enabled site

Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

A

Ancora Heart

Status

Enrolling

Conditions

Dilated Cardiomyopathy
Heart Failure With Reduced Ejection Fraction (HFrEF)

Treatments

Device: AccuCinch Ventricular Restoration System
Drug: Guideline-Directed Medical Therapy

Study type

Interventional

Funder types

Industry

Identifiers

NCT04331769
5019

Details and patient eligibility

About

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).

Full description

The CORCINCH-HF Study is a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation of the AccuCinch Ventricular Restoration System. Subjects will be randomized in a 1:1 ratio: Treatment group: AccuCinch Ventricular Restoration System plus guideline-directed medical therapy (GDMT) (n~200) Control group: Guideline-directed medical therapy (GDMT) (n~200)

Enrollment

400 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18-years or older
  • Ejection Fraction: ≥20% and ≤40% measured by transthoracic echocardiography (TTE) and assessed by an echocardiography (echo) core lab
  • LV end-diastolic diameter ≥55 mm measured by TTE and assessed by an echo core lab

Symptom Status:

  • NYHA III,
  • NYHA ambulatory IV, or
  • NYHA II with a heart failure hospitalization within the prior 12 months (of signing the consent)
  • Able to complete six-minute walk test with distance between 100 m and 450 m.

Diagnosis and treatment for heart failure should be established at least 90 days before the date of consent. Subjects should be on stable, optimally titrated medical therapy for at least 30 days, as recommended according to current guidelines as standard-of-care for Heart Failure therapy, with any intolerance documented.

  • "Stable" is defined as no more than a 100% increase or a 50% decrease of total daily doses. Medication changes within this range do not require any additional waiting before the screening assessments
  • When a total daily dose increase or decrease exceeds that which is considered stable, the screening TTE and CT will be postponed 30 days after the medication change
  • When additional titration is required to optimize a subject's medication that exceeds what is considered stable, the screening TTE and CT will be postponed at least 30 days after achieving the optimal dose (provided the optimal dose remains outside of the stable parameters)
  • When a dose-for-dose equivalent change in the class of medication change is made, no additional waiting is required before the screening assessments
  • When a change in class medication change exceeds what is considered stable, OR a new class of medication is added, the screening TTE and CT will be postponed 30 days after the medication change
  • If an SGLT2 inhibitor is added to a subject's medications, the screening TTE and CT will be postponed at least 30 days after the addition
  • If an SGLT2 inhibitor dose changes per the stable definition above, no additional waiting is required before the screening assessments
  • If an SGLT2 inhibitor dose change exceeds what is considered stable, the screening TTE and CT will be postponed at least 30 days after achieving the optimal dose (provided the dose remains outside of the stable parameters)
  • When applicable, for guideline-directed device-based therapies: a CRT device must be placed > 90 days before the screening TTE and CT, and an ICD must be placed > 30 days before the screening TTE and CT
  • Able and willing to complete all qualifying diagnostic and functional tests, willing to accept blood product transfusion if required and agrees to comply with study follow-up schedule

Exclusion criteria

Cardiovascular

  • Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 90 days prior to consent
  • Untreated clinically significant coronary artery disease (CAD) requiring revascularization
  • Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation
  • Suboptimal ventricular anatomy or wall thickness as determined from screening echocardiography and/or CT scan
  • Heart failure on the basis other than ischemic or non-ischemic dilated cardiomyopathy (e.g., hypertrophic cardiomyopathy, amyloid cardiomyopathy, restrictive cardiomyopathy, uncorrected congenital heart disease, constrictive pericarditis)
  • Hemodynamic instability within 30 days prior to the implant defined as subject requiring inotropic support or mechanical hemodynamic support
  • Any planned cardiac surgery or interventions within the next 180 days post-randomization (including therapeutic right heart procedures)
  • Active bacterial endocarditis
  • Severe RV dysfunction assessed by right heart catheterization (RHC) and/or TTE
  • Fixed pulmonary hypertension with PA systolic pressure >70 mmHg not responsive to vasodilator therapy

History of any stroke within the prior 90 days of consent or documented Modified Rankin Scale ≥ 2 disability from any prior stroke

Valvular

  • Mitral regurgitation grade 3+ (moderate-severe) or 4+ (severe)
  • Untreated degenerative (primary) mitral valve disease (mild prolapse with no need for intervention is allowable)
  • Prior mitral or aortic valve replacement
  • Tricuspid regurgitation grade 4+ (severe)
  • Moderate or severe aortic valve stenosis (AVA less than 1.5 cm2 or peak velocity AV Vmax >300 cm/sec)

Aortic regurgitation grade 2+ (moderate), 3+ (moderate-severe), or 4+ (severe)

Procedural

  • Anatomical pathology or constraints preventing appropriate access/implant of the AccuCinch Ventricular Restoration System (e.g., femoral arteries will not support a 20F Introducer sheath)
  • Renal insufficiency (i.e., eGFR of <25 ml/min/1.73 m2)
  • Subjects in whom anticoagulation during the procedure is contraindicated
  • Subjects in whom 90 days of antiplatelet therapy is contraindicated
  • Known allergy to nitinol, polyester, or polyethylene

Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure

General

  • Life expectancy <1 year due to non-cardiac conditions
  • Currently participating in another interventional investigational study
  • Subjects on high dose steroids or immunosuppressant therapy
  • Female subjects who are pregnant, of child-bearing potential without a documented birth control method, or who are lactating

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

400 participants in 2 patient groups

Device group: AccuCinch Ventricular Restoration System
Experimental group
Description:
Subjects in this arm will receive the AccuCinch Ventricular Restoration System
Treatment:
Device: AccuCinch Ventricular Restoration System
Control group: Guideline-Directed Medical Therapy
Active Comparator group
Description:
Subjects in this arm will receive guideline-directed medical therapy (GDMT)
Treatment:
Drug: Guideline-Directed Medical Therapy

Trial contacts and locations

111

Loading...

Central trial contact

Michael Zapien, MS, CCRA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems